Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy.
Gregory
C R
CR
Comparative Transplantation Laboratory, School of Veterinary Medicine, University of California, Davis 95616-8745, USA.
Stewart
A
A
Sturges
B
B
DeManvelle
T
T
Cannon
A
A
Ortega
T
T
Harb
M
M
Morris
R E
RE
D000814:Aniline Compounds / Q000493:pharmacokinetics; D000818:Animals; D003437:Crotonates; D004283:Dog Diseases / Q000188:drug therapy* / Q000276:immunology; D004285:Dogs; D005260:Female; D006885:Hydroxybutyrates / Q000493:pharmacokinetics; D007154:Immune System Diseases / Q000188:drug therapy / Q000662:veterinary*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000662:veterinary*; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D009570:Nitriles; D013577:Syndrome; D014052:Toluidines
D000814:Aniline Compounds; D003437:Crotonates; D006885:Hydroxybutyrates; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide; D000077339:Leflunomide